Karyopharm Therapeutics Updates Data For Selinexor In Solid Tumors At 2014 American Society of Clinical Oncology Annual Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with advanced or metastatic solid tumors and an ongoing Phase 1b food effects study of Selinexor in patients with advanced sarcomas at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from these trials indicate that first-in-class oral Selinexor showed continued evidence of anti-cancer activity as a single agent across a broad range of solid tumor indications in patients with progressive disease whose cancers had relapsed after, or were refractory to, multiple prior therapies.

Help employers find you! Check out all the jobs and post your resume.

Back to news